Алла Александровна Божок
Saint Petersburg State Pediatric Medical University · 73 works · 2,743 citations · h-index 10
Top works
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
- Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
- Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancer
- Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
- The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer
- Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1–2, T3N0–1, T4N0M0)
- Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study
- Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.
- Prognostic and predictive factors in breast cancer
- Evaluation of the scientific results of the study entitled “Opportunities for surgical treatment of patients with stage IV breast cancer” performed by Russian Society of Oncomammologists (RSOM)
- Anastrazol (A) vs tamoxifen (T) vs combine (A+T) as neoadjuvant endocrine therapy of postmenopausal breast cancer patients
- Clinical and morphological characteristics of skin and subcutaneous fat damage after surgical treatment and radiation therapy in patients with breast cancer (literature review)
- Circumlateral vertical mastopexy in tuberous breast deformity
- Preoperative hormonal therapy vs chemotherapy in postmenopausal ER-positive breast cancer patients
- Predictive multigenic scale. Analysis of own results in metastatic breast cancer
- [Breast-preserving (conservative) therapy of breast cancer].
- [Inflammatory breast carcinoma and prognosticators of efficacy of primary chemotherapy].
- P85 Direct comparison of primary (neoadjuvant) endocrine therapy vs primary chemotherapy in postmenopausal women with ER-positive breast cancer
- [HER2-positive breast cancer: standard and double targeted therapy].